AmbioPharm Invests US$28mn for the Expansion of Pharmaceutical Manufacturing Site in Shanghai, China
Introduction:
AmbioPharm invests US$28 million for the expansion of pharmaceutical manufacturing site in Shanghai, China.
Features:
This new facility marks a significant 70,000-square-foot expansion at Shanghai site, aimed at strengthening the global manufacturing capabilities.
The expansion of building 2 will incorporate advanced fragment-based peptide synthesis technology, with multiple 1000L to 3000L solid-phase and liquid-phase synthesis lines.
The new facility will substantially boost production capacity, enabling the manufacturing of over 8 metric tons of crude peptide annually.
This production will be complemented by existing downstream purification and isolation processes at the Shanghai site and further supported by U.S. facility in North Augusta, South Carolina.
The new capabilities will allow to meet the rising demand for therapeutic peptides and better serve customers worldwide.
The new manufacturing facility is anticipated to be fully operational by the second half of 2025.
Specifications:
| Name : | AmbioPharm |
| Type : | New Construction |
| Budget : | US$28 million |
| Year : | 2025 |
